Most patients receiving a GLP-1 receptor agonist (RA) and a biologic continue co-therapy for over a year with few treatment-related adverse events.

Researchers from the Institute for Advanced Chemistry of Catalonia (IQAC) of the Spanish National Research Council (CSIC) ...

Please provide your email address to receive an email when new articles are posted on . Persistence was defined as a lack of a treatment gap of more than two doses, with more than half of refills ...